<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01108159</url>
  </required_header>
  <id_info>
    <org_study_id>HEM0013</org_study_id>
    <secondary_id>1081737-100-DHAAT</secondary_id>
    <secondary_id>SU-09092009-3820</secondary_id>
    <secondary_id>16329</secondary_id>
    <nct_id>NCT01108159</nct_id>
  </id_info>
  <brief_title>Integrated Whole-Genome Analysis of Hematologic Disorders</brief_title>
  <official_title>Integrated Whole-Genome Analysis of Hematologic Disorders Using High-Throughput Sequencing and Array Technologies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      We will use new technologies to look at the DNA, RNA, proteins, and metabolites in the
      disease-containing blood, bone marrow, or tissue and normal cells from the skin. Our goal is
      to analyze all of the genes in the diseased and normal skin sample. By comparing the results
      of the diseased sample and normal skin cells and the results of the two types of genetic
      information (DNA and RNA), we should be able to identify genetic changes that are important
      for the initiation, progression, or treatment response of that particular disorder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">August 2, 2013</completion_date>
  <primary_completion_date type="Actual">August 2, 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>to identify mutations, changes in DNA copy number, structural rearrangements, or altered coding and non-coding RNA expression</measure>
    <time_frame>sample collection at time of routine visit</time_frame>
  </primary_outcome>
  <enrollment type="Actual">35</enrollment>
  <condition>Hematologic Diseases</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin Biopsy</intervention_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, bone marrow, skin biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        participants with hematologic disorders
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older

          2. Patient meets the clinical and/or pathologic criteria for the hematologic disorder
             being examined.

          3. Patient is willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.

        Exclusion Criteria:

          1. Less than 18 years of age

          2. Patient is not willing to provide a skin biopsy and five 10 mL tubes of peripheral
             blood.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James L Zehnder</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>April 19, 2010</study_first_submitted>
  <study_first_submitted_qc>April 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2010</study_first_posted>
  <last_update_submitted>May 29, 2018</last_update_submitted>
  <last_update_submitted_qc>May 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Jason D. Merker</investigator_full_name>
    <investigator_title>Assistant Professor of Pathology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

